Ibm spss statistics 20.0
![ibm spss statistics 20.0 ibm spss statistics 20.0](https://i.ytimg.com/vi/L0ctWA2ta_U/maxresdefault.jpg)
![ibm spss statistics 20.0 ibm spss statistics 20.0](https://ars.els-cdn.com/content/image/3-s2.0-B9780128157640000277-f07_01-01-9780128157640.jpg)
Of 67 respondents, 91% (n = 61) were under adult care at the time of survey completion. Here, an online survey captured patient perceptions of the challenges faced by patients with EoE in the United States during transition to adult healthcare, and which resources, if implemented, could better support transition. Patients with a childhood diagnosis require ongoing disease management in adulthood however, knowledge of the patient experience during pediatric to adult healthcare transition is lacking. Įosinophilic esophagitis (EoE) is a chronic immune-mediated disease.
IBM SPSS STATISTICS 20.0 LICENSE
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. All authors agree to be accountable for all aspects of the work presented herein. Nandini Hadker and Irana Kolev additionally contributed to the acquisition and analysis of the data. This research has been presented in accepted abstracts and poster presentations at both North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2019 and Western Society of Allergy, Asthma & Immunology (WSAAI) 2020, and the NASPGHAN 2019 abstract has been published in Journal of Pediatric Gastroenterology and Nutrition.Īuthor roles: All authors contributed to the conception of the work, the interpretation of data, and the drafting and critical review of the manuscript, and provided their final approval of the submitted version. Our manuscript reports original, unpublished research, and is not published, accepted or under consideration for publication elsewhere or in any other language. This study was funded by Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies. Falk has received research funding from Adare Pharmaceuticals, Allakos, Receptos/Celgene, Regeneron Pharmaceuticals and Shire, a Takeda company, and serves as a consultant to Adare Pharmaceuticals, Allakos and Shire, a Takeda company. Juethner is an employee of Takeda Pharmaceuticals USA, Inc., and a stockholder of Takeda Pharmaceuticals Company Limited. Williams is an employee of Shire Human Genetic Therapies, Inc., a Takeda company, and a stockholder of Takeda Pharmaceuticals Company Limited. Kolev was an employee of Trinity Partners, LLC at the time of the study, received consulting fees from Shire, a Takeda company, to conduct the study, and is a current employee of Millennium Pharmaceuticals, Inc., a Takeda company and a stockholder of Takeda Pharmaceutical Company Limited. Hadker is an employee of Trinity Partners, LLC and received consulting fees from Shire, a Takeda company, to conduct the study.
![ibm spss statistics 20.0 ibm spss statistics 20.0](https://i.pinimg.com/originals/fd/05/23/fd052357f061ee6752395a4d3d903ace.jpg)
Furuta is a founder of EnteroTrack and a consultant for Shire, a Takeda company. Robinson is a consultant for Shire, a Takeda company. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site ( J. Supplemental digital content is available for this article. Falk, MD, MS Professor of Medicine, Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Hospital of the University of Pennsylvania, PCAM South Pavilion, 7th Floor, 3400 Civic Center Boulevard, Philadelphia, PA 19104-4311 (e-mail: ). ||Department of Internal Medicine, Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.Īddress correspondence and reprint requests to Gary W. §Takeda Pharmaceuticals USA, Inc., Lexington, MA ‡Shire Human Genetic Therapies, Inc., a Takeda company, Cambridge, MA ∗Gastrointestinal Eosinophilic Diseases Program, Department of Pediatrics, University of Colorado School of Medicine, Digestive Health Institute, Children's Hospital of Colorado Aurora, CO